Cancer immunotherapies, particularly ICBs targeting the PD-1/PD-L1 and CTLA-4 immune checkpoints, have made great success in a variety of malignancies over the past decade and have revolutionized treatment strategies for many cancer patients. The gene discussed is CD274; the disease is cancer.